199 related articles for article (PubMed ID: 36948674)
41. Surgical treatment of atypical metastasis from renal cell carcinoma (RCC).
Antonelli A; Arrighi N; Corti S; Legramanti S; Zanotelli T; Cozzoli A; Cunico SC; Simeone C
BJU Int; 2012 Dec; 110(11 Pt B):E559-63. PubMed ID: 22639956
[TBL] [Abstract][Full Text] [Related]
42. The Promise of Neoadjuvant and Adjuvant Therapies for Renal Cancer.
Leow JJ; Ray S; Dason S; Singer EA; Chang SL
Urol Clin North Am; 2023 May; 50(2):285-303. PubMed ID: 36948672
[TBL] [Abstract][Full Text] [Related]
43. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.
Bex A; Jonasch E; Kirkali Z; Mejean A; Mulders P; Oudard S; Patard JJ; Powles T; van Poppel H; Wood CG
Eur Urol; 2010 Dec; 58(6):819-28. PubMed ID: 20828919
[TBL] [Abstract][Full Text] [Related]
44. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B
Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171
[TBL] [Abstract][Full Text] [Related]
45. Targeted therapy for locally advanced renal cell carcinoma.
Jonasch E; Tannir NM
Target Oncol; 2010 Jun; 5(2):113-8. PubMed ID: 20625844
[TBL] [Abstract][Full Text] [Related]
46. Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: How to Apply New Evidence in Clinical Practice.
Soares A; Maia MC; Vidigal F; Marques Monteiro FS
Oncology; 2020; 98(1):1-9. PubMed ID: 31514196
[TBL] [Abstract][Full Text] [Related]
47. Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma.
Wood E; Donin N; Shuch B
Urol Clin North Am; 2020 Aug; 47(3):345-358. PubMed ID: 32600536
[TBL] [Abstract][Full Text] [Related]
48. Is there a role for presurgical therapy for renal cell carcinoma?
Calabrò F; Sternberg CN
Expert Rev Anticancer Ther; 2010 Jun; 10(6):807-12. PubMed ID: 20553206
[TBL] [Abstract][Full Text] [Related]
49. Reply to Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies?
Richey SL; Culp SH; Jonasch E; Matin SF; Wood CG; Tannir NM
Ann Oncol; 2011 May; 22(5):1243. PubMed ID: 21521725
[No Abstract] [Full Text] [Related]
50. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
[TBL] [Abstract][Full Text] [Related]
51. Concordance of Pathologic Features Between Metastatic Sites and the Primary Tumor in Surgically Resected Metastatic Renal Cell Carcinoma.
Psutka SP; Cheville JC; Costello BA; Stewart-Merrill SB; Lohse CM; Leibovich BC; Boorjian SA; Thompson RH
Urology; 2016 Oct; 96():106-113. PubMed ID: 27453217
[TBL] [Abstract][Full Text] [Related]
52. Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.
Kim DY; Karam JA; Wood CG
World J Urol; 2014 Jun; 32(3):631-42. PubMed ID: 24744223
[TBL] [Abstract][Full Text] [Related]
53. Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma.
Crispen PL; Blute ML
Curr Urol Rep; 2012 Feb; 13(1):38-46. PubMed ID: 22105577
[TBL] [Abstract][Full Text] [Related]
54. Targeted therapies for non-clear renal cell carcinoma.
Singer EA; Bratslavsky G; Linehan WM; Srinivasan R
Target Oncol; 2010 Jun; 5(2):119-29. PubMed ID: 20680492
[TBL] [Abstract][Full Text] [Related]
55. Multi-modal treatment for metastatic renal cancer: the role of surgery.
Russo P
World J Urol; 2010 Jun; 28(3):295-301. PubMed ID: 20364382
[TBL] [Abstract][Full Text] [Related]
56. The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry database.
Vaishampayan U; Vankayala H; Vigneau FD; Quarshie W; Dickow B; Chalasani S; Schwartz K
Clin Genitourin Cancer; 2014 Apr; 12(2):124-9. PubMed ID: 24225251
[TBL] [Abstract][Full Text] [Related]
57. Surgical intervention in patients with metastatic renal cancer: current status of metastasectomy and cytoreductive nephrectomy.
Russo P
Nat Clin Pract Urol; 2004 Nov; 1(1):26-30. PubMed ID: 16474463
[TBL] [Abstract][Full Text] [Related]
58. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.
Massari F; Di Nunno V; Gatto L; Santoni M; Schiavina R; Cosmai L; Brunocilla E; Ardizzoni A; Porta C
Target Oncol; 2018 Dec; 13(6):705-714. PubMed ID: 30324488
[TBL] [Abstract][Full Text] [Related]
59. Indications, complications, and outcomes following surgical management of locally advanced and metastatic renal cell carcinoma.
González J; Gaynor JJ; Alameddine M; Esteban M; Ciancio G
Expert Rev Anticancer Ther; 2018 Mar; 18(3):237-250. PubMed ID: 29353520
[TBL] [Abstract][Full Text] [Related]
60. Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens.
Wolf JS; Aronson FR; Small EJ; Carroll PR
J Surg Oncol; 1994 Jan; 55(1):7-13. PubMed ID: 8289458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
